Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc RARE

Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product... see more

Recent & Breaking News (NDAQ:RARE)

Ultragenyx Reports Second Quarter 2017 Financial Results and Corporate Update

GlobeNewswire July 27, 2017

Ultragenyx to Host Conference Call for Second Quarter 2017 Financial Results and Corporate Update

GlobeNewswire July 21, 2017

Ultragenyx Provides Regulatory Update on Burosumab (KRN23)

GlobeNewswire June 23, 2017

Ultragenyx to Present at Goldman Sachs 38th Annual Global Healthcare Conference

GlobeNewswire June 7, 2017

Ultragenyx to Present at Jefferies Global Healthcare Conference

GlobeNewswire June 1, 2017

Research Reports Initiation on Biotech Stocks -- Kite Pharma, Arrowhead Pharma, Ultragenyx Pharma, and Jazz Pharma

PR Newswire May 31, 2017

Ultragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License Application and Marketing Authorization Application Filed and Accepted for Review; FDA Grants Priority Review Status

GlobeNewswire May 23, 2017

Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc.

Business Wire May 15, 2017

Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference

GlobeNewswire May 10, 2017

Ultragenyx Reports First Quarter 2017 Financial Results and Corporate Update

GlobeNewswire May 4, 2017

Ultragenyx to Host Conference Call for First Quarter 2017 Financial Results and Corporate Update

GlobeNewswire April 28, 2017

Ultragenyx Initiates Global Phase 3 Study of UX007 in Glut1 DS Patients with Disabling Movement Disorders

GlobeNewswire April 27, 2017

Research Reports Coverage on Biotech Stocks -- Ultragenyx Pharma, Chimerix, Coherus Biosciences, and Omeros

PR Newswire April 27, 2017

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  April 19, 2017

Ultragenyx Appoints Deborah Dunsire, M.D., to Board of Directors

GlobeNewswire April 10, 2017

12 Biggest Mid-Day Losers For Thursday

Benzinga.com  April 6, 2017

Ultragenyx and Kyowa Kirin International Announce Positive Data from Pediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia

GlobeNewswire April 6, 2017

15 Biggest Mid-Day Losers For Thursday

Benzinga.com  March 23, 2017

Wedbush Lowers Ultragenyx Pharmaceutical Price Target On New Outlook

Benzinga.com  March 23, 2017

The Market In 5 Minutes

Benzinga.com  March 23, 2017